Has Rusdeep Mundae, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,849 in general payments to Rusdeep Mundae, MD across 87 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rusdeep Mundae, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rusdeep Mundae, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rusdeep Mundae, MD

Ophthalmology · Chula Vista, CANPI 1811488687

Payments from drug & device makers

$5,849in general payments, 2019–2025

Across 87 payments — averaging $67.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$1K
Biotissue Holdings Inc.$917
Regeneron Healthcare Solutions, Inc.$571
Alimera Sciences, Inc.$460
Mallinckrodt Hospital Products Inc.$344
Genentech USA, Inc.$320
plus $2K from 17 others

What the payments were for

Speaking & faculty fees$4608%
Food & beverage$5,38992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	11	$1,068
Biotissue Holdings Inc.	6	$917
Regeneron Healthcare Solutions, Inc.	5	$571
Alimera Sciences, Inc.	1	$460
Mallinckrodt Hospital Products Inc.	13	$344
Genentech USA, Inc.	4	$320
AbbVie	13	$304
Apellis Pharmaceuticals, Inc.	2	$241
Surgical Specialties Corporation (US), Inc. (dba Corza Medical)	5	$220
Tarsus Pharmaceuticals, Inc.	5	$213
Genentech, Inc.	3	$183
Dutch Ophthalmic, USA	1	$172
Astellas Pharma US Inc	2	$154
Eyepoint US, Inc.	1	$147
Johnson & Johnson Surgical Vision, Inc.	1	$137
Regeneron	2	$125
ANI Pharmaceuticals, Inc.	3	$58
Dompe US, Inc.	2	$53
Bausch & Lomb Americas Inc.	2	$48
Thea Pharma Inc.	2	$44
Sun Pharmaceutical Industries Inc.	1	$33
Oyster Point Pharma, Inc.	1	$21
Johnson & Johnson Vision Care, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,849 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California →

Medicare billing

Part B allowed, 2024

$68,701

Medicare patients

210

Services billed

620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	17	$1,060
Timolol Maleate	15	$317
Ketorolac Tromethamine	12	$291
Ofloxacin	15	$180
Latanoprost	21	$131
Brimonidine Tartrate	12	$93

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Chula Vista

Nisha AcharyaSan Francisco$33M
David WirtaNewport Beach$18.4M
Michael IpPasadena$10.2M
Raymond DouglasBeverly Hills$9.7M
Sherif El HaraziGlendale$9.2M
Daniel SchwartzSan Francisco$8M
Nikolas Londonla Jolla$6.1M
Michael BerlinWest Hollywood$5.7M
Steven JacobsonLos Angeles$4.7M
Peter WinArcadia$4.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →